Abstract
p53, the “guardian of the genome” and the most mutated gene in cancer presents a considerable therapeutic opportunity as well as a challenge. In the past decade, several therapeutic strategies have been developed that aim to take advantage of a wealth of knowledge about p53, including insights into the biology and patho-biology of p53. Nevertheless, considerable challenges remain, not least as a result of tissue- and cancer-specific differences in p53 regulation and/or function. p53 does not act in the same manner in all tissues or in the cancers arising from them. Nor is p53 regulated in the same way in the wide variety of tissues from which cancers develop. Therefore, potential strategies for therapeutic targeting need to be tailored to each tumour/tissue type. This review summarises some of these tissue- and cancer-specific issues to suggest how different strategies are required for cancers arising from different tissues and to illustrate the complexities of therapeutic targeting of p53.
Keywords: p53, MDM2, cancer, therapy, apoptosis, senescence, colorectal cancer, renal cancer, oropharyngeal squamous cell carcinoma, hepatocellular carcinoma, hepatitis B virus, human papilloma virus, Nutlin-3, MI-219, MI-319, PRIMA, small molecule inhibitors, tissues
Current Pharmaceutical Design
Title: Tissue-Specific Therapeutic Targeting of p53 in Cancer: One Size Does Not Fit All
Volume: 17 Issue: 6
Author(s): Nikolina Vlatkovic, Kerryanne Crawford, Carlos P. Rubbi and Mark T. Boyd
Affiliation:
Keywords: p53, MDM2, cancer, therapy, apoptosis, senescence, colorectal cancer, renal cancer, oropharyngeal squamous cell carcinoma, hepatocellular carcinoma, hepatitis B virus, human papilloma virus, Nutlin-3, MI-219, MI-319, PRIMA, small molecule inhibitors, tissues
Abstract: p53, the “guardian of the genome” and the most mutated gene in cancer presents a considerable therapeutic opportunity as well as a challenge. In the past decade, several therapeutic strategies have been developed that aim to take advantage of a wealth of knowledge about p53, including insights into the biology and patho-biology of p53. Nevertheless, considerable challenges remain, not least as a result of tissue- and cancer-specific differences in p53 regulation and/or function. p53 does not act in the same manner in all tissues or in the cancers arising from them. Nor is p53 regulated in the same way in the wide variety of tissues from which cancers develop. Therefore, potential strategies for therapeutic targeting need to be tailored to each tumour/tissue type. This review summarises some of these tissue- and cancer-specific issues to suggest how different strategies are required for cancers arising from different tissues and to illustrate the complexities of therapeutic targeting of p53.
Export Options
About this article
Cite this article as:
Vlatkovic Nikolina, Crawford Kerryanne, P. Rubbi Carlos and T. Boyd Mark, Tissue-Specific Therapeutic Targeting of p53 in Cancer: One Size Does Not Fit All, Current Pharmaceutical Design 2011; 17 (6) . https://dx.doi.org/10.2174/138161211795222568
DOI https://dx.doi.org/10.2174/138161211795222568 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer
Current Cancer Drug Targets Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention
Current Drug Targets Biological Rationales and Clinical Applications of Temperature Controlled Hyperthermia - Implications for Multimodal Cancer Treatments
Current Medicinal Chemistry Apoptosis-Inducing Effects of Amaryllidaceae Alkaloids
Current Medicinal Chemistry Imaging Requirements for Personalized Medicine: The Oncologists Point of View
Current Pharmaceutical Design Inhibitory Smad7: Emerging Roles in Health and Disease
Current Molecular Pharmacology Adverse Effects and Safety of Etirinotecan Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review
Current Cancer Therapy Reviews Armed Oncolytic Adenoviruses and Polymer-shielded Nanocomplex for Systemic Delivery
Current Cancer Therapy Reviews Studies on Structures and Functions of Kinases leading to Prostate Cancer and Their Inhibitors
Current Enzyme Inhibition Nanocarriers for the Simultaneous Co-Delivery of Therapeutic Genes and Anticancer Drugs
Current Pharmaceutical Biotechnology High Order Texture-Based Analysis in Biomedical Images
Current Medical Imaging Transactivation of EGFR by G Protein-Coupled Receptor in the Pathophysiology of Intimal Hyperplasia
Current Vascular Pharmacology Molecular Pathways in the Progression of Hormone-Independent and Metastatic Prostate Cancer
Current Cancer Drug Targets Analysis of the Potential for HIV-1 Vpr as an Anti-Cancer Agent
Current HIV Research Novel Function of Beta 2 Glycoprotein I in Angiogenesis
Current Angiogenesis (Discontinued) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
Current Pharmaceutical Design Targeting Stem Cells-Clinical Implications for Cancer Therapy
Current Stem Cell Research & Therapy Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview
Anti-Cancer Agents in Medicinal Chemistry Cancer Electrogene Therapy with Interleukin-12
Current Gene Therapy Effective Inhibition of Mitochondrial Metabolism by Cryptotanshinone in MDA-MB231 cells: A Proteomic Analysis
Current Proteomics